TheranosticTrials.org

Clinical Trial · NCT06851663

Trop2-targeted immunoPET Imaging of Solid Tumors

Overview

This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.

Sponsor

RenJi Hospital

Phase

Phase 2/3

Contacts

Weijun Wei, Ph.D. & M.D. (CONTACT)

wwei@shsmu.edu.cn

15000083153

Weijun Wei, Ph.D. & M.D. (PRINCIPAL_INVESTIGATOR)

Jianjun Liu, Ph.D. & M.D. (STUDY_CHAIR)

ClinicalTrials.gov

NCT06851663

Drug / Compound

NOTA-T4

Isotope(s):
Target(s):
  • Trop-2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA

PSMA

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

RESCA-RT4

Isotope(s):
Target(s):
  • Trop-2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: RESCA

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
  • * Aged 18-75 year-old and of either sex
  • Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;

Exclusion

  • Severe hepatic and renal insufficiency;
  • * Pregnancy；
  • Allergic to single-domain antibody radiopharmaceuticals.